After Cantor Fitzgerald and Oppenheimer gave Strongbridge Biopharma Plc (NASDAQ: SBBP) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Strongbridge Biopharma Plc today and set a price target of $18. The company’s shares closed yesterday at $4.79.
Fein wrote:
“We view this observation as a positive and supportive of a broader patient base that could stand to benefit from Recorlev treatment. Additionally in patients with or without DM, significant improvement was noted in LDL-cholesterol, weight, BMI, and waist circumference, suggesting possible impact for longer term cardiovascular effects. In DM patients, improvements were more pronounced for hemoglobin A1c (HbA1c) and fasting blood glucose (FBG) levels during the maintenance phase compared to non-DM patients, along with instances of reduced diabetic medication. We view this as a relevant connection specifically in the context of diabetes comorbidity in CS patients. Discontinuation due to TEAEs was characterized as low for both DM and non-DM groups.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.1% and a 47.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Strongbridge Biopharma Plc has an analyst consensus of Strong Buy, with a price target consensus of $14.50, representing a 202.7% upside. In a report issued on March 11, Laidlaw also maintained a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
Strongbridge Biopharma Plc’s market cap is currently $226M and has a P/E ratio of 8.43. The company has a Price to Book ratio of -36.13.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SBBP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.
